GlobeNewswire Inc.··NaOculis Gears Up for Pivotal 2026 With Six Major Clinical Readouts Planned
Oculis announces investor conference participation ahead of landmark 2026 featuring multiple drug readouts and regulatory designations across three lead programs.
OCSOCSAWclinical trialsbiopharmaceutical